SK Biopharmaceuticals326030
SK Biopharmaceuticals (326030) Preliminary Earnings, Nov 5, 2026
Filing date ·
SK Biopharmaceuticals reported preliminary Q3 2026 results (consolidated): Revenue of KRW 258.4 billion (+34.8% year over year), operating profit of KRW 116.3…
Sign in to read this filing in detail
Continue to the filing details and any available analysis after signing in.
Filing lists and official source links are available without signing in.